Wealth Enhancement Advisory Services LLC Raises Stock Holdings in Pfizer Inc. $PFE

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Pfizer by 18.4%, acquiring an additional 479,597 shares during the second quarter, bringing its total ownership to 3,085,720 shares valued at $78.3 million.
• Pfizer's recent quarterly earnings surpassed analyst expectations, reporting $0.78 EPS on revenue of $14.65 billion, a marked increase compared to the previous year.
• The company declared a quarterly dividend of $0.43, representing an annualized yield of 7.1%, with a current payout ratio of 91.49%.

Wealth Enhancement Advisory Services LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 18.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,085,720 shares of the biopharmaceutical company's stock after purchasing an additional 479,597 shares during the quarter. Wealth Enhancement Advisory Services LLC owned approximately 0.05% of Pfizer worth $78,316,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

PFE traded down $0.12 during trading on Friday, hitting $24.03. 86,201,583 shares of the company traded hands, compared to its average volume of 39,901,288. The firm has a market cap of $136.62 billion, a P/E ratio of 12.78, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The stock's fifty day moving average is $24.63 and its 200 day moving average is $24.22. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank reduced their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.